AlphAIalphai — Financial news for AI agents
BenzingaOCT 133 min read$TVRD

Why Is Tvardi Therapeutics Stock Falling Today? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics Inc. ( NASDAQ:TVRD ) stock is falling on Monday with a session volume of 5.56 million versus the average volume of 42.08 thousand, as per data from Benzinga Pro.

Original reporting
Benzinga · Vandana Singh
Published Oct 13, 2025, 6:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 13, 2025, 7:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Is Tvardi Therapeutics Stock Falling Today? - Tvardi Therapeutics (NASDAQ:TVRD) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$TVRDBearishMed
01

Why it matters

The clinical trial failure has led to a sharp decline in stock price, increased volatility, and potential reevaluation of the company's valuation.

02

Market read

The event is highly relevant to biotech investors and traders, especially those holding or considering TVRD stock or similar biotech assets.

03

What to watch

The company's cash position and upcoming catalysts could influence recovery prospects; broader market conditions may also impact stock performance.

Timing: immediate, as the news was published today and has caused a stock decline.

Background

Tvardi Therapeutics is a biotech firm focusing on lung disease treatments. The recent failure of a key clinical trial has negatively impacted investor confidence.

Company-level read

Ticker impact

$TVRDBearishHigh confidence
Context

The news directly impacts Tvardi Therapeutics due to clinical trial failure.

Expected impact

Short-term decline of approximately 15-20%, with potential stabilization or rebound if company provides positive updates or alternative pipeline news.

Evidence & confidence

The news reports a failed clinical trial, a critical event for biotech stocks, which historically results in immediate stock price drops. The high trading volume indicates strong market reaction.

Market effects

Sector

Potential negative sentiment spreading to biotech and healthcare sectors, especially companies with similar clinical trial risks.

Regional

Limited to US markets, as the company is NASDAQ-listed.

Global

Low, as the news pertains to a specific biotech company without broader industry or global implications.

Counterpoint

What could challenge this read

The stock decline may be an overreaction; positive developments in other pipeline candidates could offset the setback.

Key entities

  • Company
    Tvardi Therapeutics Inc.

    A biotech company developing therapies for lung diseases.

  • Event
    Clinical Trial for Lung Disease Candidate

    A pivotal clinical trial that failed to demonstrate clinical benefit, leading to stock decline.

Read at source← All news

Related articles

JUL 7
$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

investorideas.com4 min
JUL 7
$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.

rttnews.com3 min
JUL 7
$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.

benzinga.com4 min
JUL 7
$TVRDMedAI 8/10

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug of TTI-101. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional PK with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60%. It plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and funding; webcast July 7, 8:30am ET.

manilatimes.net4 min
JUN 30
$UPCMed

Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

rttnews.com6 min